BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MK-2214 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of MK-2214\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07033494-799@assetmemo.bio
DTSTAMP:20261121T005825Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:MK-2214: Phase 2 readout est. (NCT07033494)
DESCRIPTION:MK-2214\, phase 2\, Alzheimer's Disease.\nStudy: A Clinical Stu
 dy of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)\nEsti
 mated primary completion: 30 April 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/mk-2214#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07033494
URL:https://assetmemo.bio/drug/mk-2214#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
